Insulin aspart

Insulin aspart is a rapid-acting form of insulin primarily used in the treatment of diabetes mellitus to control blood sugar levels.

Insulin Aspart Structural Formula

Brand Names

This form of insulin is commercially known under the brand names Novolog in the United States and NovoRapid in some other countries.

Mechanism of Action

Insulin aspart begins to work shortly after injection, typically showing its effects within minutes. This rapid onset allows it to closely mimic the insulin spikes that a healthy pancreas would release in response to food intake. As a result, it can be administered shortly before or after meals, offering flexibility in dosing relative to meal times.

FDA Approval

The Food and Drug Administration (FDA) granted approval for insulin aspart in June 2000, allowing it to be prescribed and sold in the United States.

Administration and Dosing

The key advantage of insulin aspart over traditional insulins is its flexibility in dosing. Patients can adjust the quantity of the drug based on their meal intake, making it easier to manage and control blood sugar levels in real-time. This tailoring of doses allows for more precise blood sugar control, reducing the risks of both hyperglycemia (high blood sugar) and hypoglycemia (low blood sugar).

See Also

• Diabetes mellitus
• Insulin
• Blood sugar level
• Food and Drug Administration

Insulin aspart Resources
Latest articles Most recent articles Ongoing trials	Wikipedia